Hyundai Bioscience Co. Ltd Total Liabilities
Hyundai Bioscience Co. Ltd total liabilities. Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) has total liabilities worth ₩28.00 Billion KRW (≈ $18.97 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Hyundai Bioscience Co. Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hyundai Bioscience Co. Ltd (2002–2025)
Total liabilities of Hyundai Bioscience Co. Ltd from 2002 to 2025. This chart illustrates how Hyundai Bioscience Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 048410 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Hyundai Bioscience Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Hyundai Bioscience Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Twin Disc Incorporated
NASDAQ:TWIN
|
USA | $181.31 Million |
|
Muang Thai Insurance Public Company Limited
BK:MTI
|
Thailand | ฿20.16 Billion |
|
GSR III Acquisition Corp. Ordinary Shares
NASDAQ:GSRT
|
USA | $10.07 Million |
|
Yibin Paper Industry Co Ltd
SHG:600793
|
China | CN¥2.93 Billion |
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
China | CN¥754.18 Million |
|
Crescent Capital BDC Inc
NASDAQ:CCAP
|
USA | $916.10 Million |
|
InPlay Oil Corp
TO:IPO
|
Canada | CA$795.00 Million |
|
PNC Infratech Limited
NSE:PNCINFRA
|
India | Rs-68.13 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Hyundai Bioscience Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hyundai Bioscience Co. Ltd (048410) total assets.
Liquidity & Leverage Metrics
Hyundai Bioscience Co. Ltd Total Liabilities Ratios Explained
Hyundai Bioscience Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hyundai Bioscience Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hyundai Bioscience Co. Ltd (2002–2025)
The table below shows the annual total liabilities of Hyundai Bioscience Co. Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩20.01 Billion ≈ $13.56 Million |
-29.20% |
| 2024-12-31 | ₩28.27 Billion ≈ $19.16 Million |
+275.85% |
| 2023-12-31 | ₩7.52 Billion ≈ $5.10 Million |
-17.28% |
| 2022-12-31 | ₩9.09 Billion ≈ $6.16 Million |
-52.04% |
| 2021-12-31 | ₩18.96 Billion ≈ $12.85 Million |
-53.86% |
| 2020-12-31 | ₩41.09 Billion ≈ $27.85 Million |
+152.92% |
| 2019-12-31 | ₩16.25 Billion ≈ $11.01 Million |
+20.13% |
| 2018-12-31 | ₩13.52 Billion ≈ $9.17 Million |
-27.32% |
| 2017-12-31 | ₩18.61 Billion ≈ $12.61 Million |
-47.09% |
| 2016-12-31 | ₩35.17 Billion ≈ $23.83 Million |
+86.97% |
| 2015-12-31 | ₩18.81 Billion ≈ $12.75 Million |
+82.23% |
| 2014-12-31 | ₩10.32 Billion ≈ $6.99 Million |
+14.19% |
| 2013-12-31 | ₩9.04 Billion ≈ $6.13 Million |
-31.33% |
| 2012-12-31 | ₩13.16 Billion ≈ $8.92 Million |
-19.23% |
| 2011-12-31 | ₩16.30 Billion ≈ $11.04 Million |
-0.42% |
| 2010-12-31 | ₩16.37 Billion ≈ $11.09 Million |
-25.22% |
| 2009-12-31 | ₩21.89 Billion ≈ $14.83 Million |
-41.11% |
| 2008-12-31 | ₩37.17 Billion ≈ $25.19 Million |
-17.26% |
| 2007-12-31 | ₩44.92 Billion ≈ $30.44 Million |
-69.25% |
| 2006-12-31 | ₩146.06 Billion ≈ $98.99 Million |
-23.73% |
| 2005-12-31 | ₩191.51 Billion ≈ $129.78 Million |
+16.88% |
| 2004-12-31 | ₩163.86 Billion ≈ $111.04 Million |
-5.94% |
| 2003-12-31 | ₩174.21 Billion ≈ $118.06 Million |
+27.61% |
| 2002-12-31 | ₩136.52 Billion ≈ $92.52 Million |
-- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.